Status:
COMPLETED
Study Of "Continuous Use" Of Celecoxib Vs. "Usual or Intermittent Use"
Lead Sponsor:
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Conditions:
Osteoarthritis, Knee
Osteoarthritis, Hip
Eligibility:
All Genders
18-80 years
Phase:
PHASE4
Brief Summary
To determine whether "continuous use" of celecoxib over a 6-month period is more efficacious than "usual or intermittent use" in preventing spontaneous osteoarthritis flares of the knee and hip.
Eligibility Criteria
Inclusion
- Subject has been diagnosed, according to American College of Rheumatology guidelines, with osteoarthritis of the hip or knee and requires non-steroidal anti-inflammatory drugs (NSAIDs) to control their osteoarthritis pain and have access to a touch-tone telephone.
Exclusion
- Subject has had surgery on index joint.
- Subject has history of rheumatoid arthritis or fibromyalgia syndrome.
- Subject has active gastrointestinal or cardiovascular disease.
Key Trial Info
Start Date :
July 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 1 2008
Estimated Enrollment :
875 Patients enrolled
Trial Details
Trial ID
NCT00139776
Start Date
July 1 2005
End Date
February 1 2008
Last Update
March 29 2021
Active Locations (124)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
Huntsville, Alabama, United States, 35801
2
Pfizer Investigational Site
Peoria, Arizona, United States, 85381
3
Pfizer Investigational Site
Phoenix, Arizona, United States, 85051
4
Pfizer Investigational Site
Anaheim, California, United States, 92801